<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="14995"><DrugName>obesity therapeutics, Modex</DrugName><DrugSynonyms><Name><Value>obesity therapeutics, Modex</Value></Name></DrugSynonyms><CompanyOriginator id="24103">IsoTis SA</CompanyOriginator><CompaniesSecondary><Company id="24103">IsoTis SA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="24103" type="Company"><TargetEntity id="4295890701" type="organizationId">Isotis Sa</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"></TargetEntity><TargetEntity id="10029883" type="MEDDRA"></TargetEntity><TargetEntity id="D009765" type="MeSH"></TargetEntity><TargetEntity id="-1640888899" type="omicsDisease"></TargetEntity><TargetEntity id="985" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="442" type="Action"><TargetEntity id="3687" type="Mechanism">Glucagon Receptor (GCGR) Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00814" type="ciTarget"><TargetEntity id="40509121426423" type="siTarget">Glucagon receptor</TargetEntity><TargetEntity id="-1607539289" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="238">Obesity</Indication></IndicationsSecondary><ActionsPrimary><Action id="442">Glucagon receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="399">Hypoglycemic agent</Action></ActionsSecondary><Technologies><Technology id="165">Cell delivery system</Technology><Technology id="586">Capsule formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>H4B</Code><Name>GLUCAGON</Name></Ephmra><Ephmra><Code>A8</Code><Name>ANTIOBESITY PREPARATIONS, EXCLUDING DIETETICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-18T09:26:14.000Z</LastModificationDate><ChangeDateLast>2003-10-28T17:03:08.000Z</ChangeDateLast><AddedDate>1997-04-23T12:02:20.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Modex has discontinued investigating the combination of various compounds with StemCells' (formerly CytoTherapeutics') encapsulated delivery technology (&lt;ulink linkID="14941" linkType="Drug"&gt;CRIB&lt;/ulink&gt;; qv) for the potential treatment of obesity [&lt;ulink linkID="243334" linkType="reference"&gt;243334&lt;/ulink&gt;], [&lt;ulink linkID="441177" linkType="reference"&gt;441177&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The obesity program involved implants containing cells producing glucagon-like peptide-1 (GLP-1) [&lt;ulink linkID="261178" linkType="reference"&gt;261178&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24103">IsoTis SA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="238">Obesity</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-02-25T00:00:00.000Z</StatusDate><Source id="441177" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="24103">IsoTis SA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="238">Obesity</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-04-23T12:02:20.000Z</StatusDate><Source id="242808" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00814"><Name>Glucagon receptor</Name><SwissprotNumbers><Swissprot>P30082</Swissprot><Swissprot>P47871</Swissprot><Swissprot>Q61606</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>